Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLD-103
- Development stage
- Phase 1
- Lead developer
- Feldan Therapeutics
- Modality
- Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intralesional
01
Overview
**FLD-103** is Feldan Therapeutics' investigational intralesional therapy for **nodular basal cell carcinoma**. It combines a proprietary peptide-based Feldan Shuttle intracellular-delivery component with an antisense oligonucleotide directed against **GLI1**, a key transcriptional effector of aberrant Hedgehog signaling in basal cell carcinoma. Local injection into tumor lesions is intended to enable intracellular GLI1 suppression, reduce tumor growth, and provide a non-surgical treatment alternative while limiting exposure of surrounding healthy tissue.
- Other names
- FLD103FLD-103FLD 103
02
Targets
GLI1
Beyond the preview
Go deeper on FLD-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLD-103.